Proactiveinvestors Australia Motif Bio PLC https://www.proactiveinvestors.com.au Proactiveinvestors Australia Motif Bio PLC RSS feed en Sat, 23 Nov 2019 08:25:26 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Motif Bio PLC trims board of five directors https://www.proactiveinvestors.com.au/companies/news/907278/motif-bio-plc-trims-board-of-five-directors-907278.html Mon, 18 Nov 2019 14:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/907278/motif-bio-plc-trims-board-of-five-directors-907278.html Motif Bio settles with contract research group https://www.proactiveinvestors.com.au/companies/news/906708/motif-bio-settles-with-contract-research-group-906708.html Mon, 11 Nov 2019 07:22:00 +1100 https://www.proactiveinvestors.com.au/companies/news/906708/motif-bio-settles-with-contract-research-group-906708.html Proactive news snapshot: Motif Bio, Midatech Pharma, Vast Resources, Greatland Gold … https://www.proactiveinvestors.com.au/companies/news/905545/proactive-news-snapshot-motif-bio-midatech-pharma-vast-resources-greatland-gold--905545.html Thu, 24 Oct 2019 14:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905545/proactive-news-snapshot-motif-bio-midatech-pharma-vast-resources-greatland-gold--905545.html Motif Bio says US Defense Department to fund trial of antibiotic iclaprim as aerosol https://www.proactiveinvestors.com.au/companies/news/905530/motif-bio-says-us-defense-department-to-fund-trial-of-antibiotic-iclaprim-as-aerosol-905530.html Thu, 24 Oct 2019 07:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/905530/motif-bio-says-us-defense-department-to-fund-trial-of-antibiotic-iclaprim-as-aerosol-905530.html Motif Bio PLC calls time on iclaprim https://www.proactiveinvestors.com.au/companies/news/215068/motif-bio-plc-calls-time-on-iclaprim-215068.html Thu, 10 Oct 2019 07:58:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215068/motif-bio-plc-calls-time-on-iclaprim-215068.html Motif Bio gets confirmation of requirements for new iclaprim trial https://www.proactiveinvestors.com.au/companies/news/904556/motif-bio-gets-confirmation-of-requirements-for-new-iclaprim-trial-904556.html Thu, 10 Oct 2019 07:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/904556/motif-bio-gets-confirmation-of-requirements-for-new-iclaprim-trial-904556.html Motif Bio raises £600,000 to cover restructuring https://www.proactiveinvestors.com.au/companies/news/903986/motif-bio-raises-600000-to-cover-restructuring-903986.html Wed, 02 Oct 2019 08:07:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903986/motif-bio-raises-600000-to-cover-restructuring-903986.html Motif Bio lender supportive ahead of key meeting with American regulator https://www.proactiveinvestors.com.au/companies/news/901836/motif-bio-lender-supportive-ahead-of-key-meeting-with-american-regulator-901836.html Mon, 02 Sep 2019 06:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/901836/motif-bio-lender-supportive-ahead-of-key-meeting-with-american-regulator-901836.html Motif Bio assessing lead drug iclaprim potential as a combatant for the life-threatening infection listeria https://www.proactiveinvestors.com.au/companies/news/900999/motif-bio-assessing-lead-drug-iclaprim-potential-as-a-combatant-for-the-life-threatening-infection-listeria-900999.html Mon, 19 Aug 2019 06:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/900999/motif-bio-assessing-lead-drug-iclaprim-potential-as-a-combatant-for-the-life-threatening-infection-listeria-900999.html Motif Bio's lender postpone's loan amortisation date by one month https://www.proactiveinvestors.com.au/companies/news/224846/motif-bio-s-lender-postpone-s-loan-amortisation-date-by-one-month-224846.html Thu, 01 Aug 2019 07:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224846/motif-bio-s-lender-postpone-s-loan-amortisation-date-by-one-month-224846.html Motif Bio to meet US regulator on September 19 to discuss trial design https://www.proactiveinvestors.com.au/companies/news/224551/motif-bio-to-meet-us-regulator-on-september-19-to-discuss-trial-design-224551.html Fri, 26 Jul 2019 06:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224551/motif-bio-to-meet-us-regulator-on-september-19-to-discuss-trial-design-224551.html Motif Bio PLC requests meeting with US regulator to discuss trial design https://www.proactiveinvestors.com.au/companies/news/223871/motif-bio-plc-requests-meeting-with-us-regulator-to-discuss-trial-design-223871.html Mon, 15 Jul 2019 06:24:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223871/motif-bio-plc-requests-meeting-with-us-regulator-to-discuss-trial-design-223871.html Motif Bio presents new iclaprim data at industry conference in California https://www.proactiveinvestors.com.au/companies/news/222643/motif-bio-presents-new-iclaprim-data-at-industry-conference-in-california-222643.html Mon, 24 Jun 2019 06:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/222643/motif-bio-presents-new-iclaprim-data-at-industry-conference-in-california-222643.html Motif Bio says US drugs regulator has encouraged it to carry out further study on antibiotic https://www.proactiveinvestors.com.au/companies/news/221611/motif-bio-says-us-drugs-regulator-has-encouraged-it-to-carry-out-further-study-on-antibiotic-221611.html Thu, 06 Jun 2019 06:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/221611/motif-bio-says-us-drugs-regulator-has-encouraged-it-to-carry-out-further-study-on-antibiotic-221611.html Motif Bio's Graham Lumsden updates on FDA discussions and iclaprim potential https://www.proactiveinvestors.com.au/companies/news/313472/motif-bio-s-graham-lumsden-updates-on-fda-discussions-and-iclaprim-potential-13472.html Fri, 24 May 2019 07:48:00 +1000 https://www.proactiveinvestors.com.au/companies/news/313472/motif-bio-s-graham-lumsden-updates-on-fda-discussions-and-iclaprim-potential-13472.html Motif Bio boss “very confident” in potential of flagship antibiotic https://www.proactiveinvestors.com.au/companies/news/220805/motif-bio-boss-very-confident-in-potential-of-flagship-antibiotic-220805.html Wed, 22 May 2019 14:14:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220805/motif-bio-boss-very-confident-in-potential-of-flagship-antibiotic-220805.html Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease https://www.proactiveinvestors.com.au/companies/news/220750/motif-bio-teams-up-with-german-university-to-see-if-iclaprim-can-help-patients-with-rare-eye-disease-220750.html Wed, 22 May 2019 06:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220750/motif-bio-teams-up-with-german-university-to-see-if-iclaprim-can-help-patients-with-rare-eye-disease-220750.html Motif Bio to present three iclaprim posters at industry conference in San Francisco next month https://www.proactiveinvestors.com.au/companies/news/220653/motif-bio-to-present-three-iclaprim-posters-at-industry-conference-in-san-francisco-next-month-220653.html Tue, 21 May 2019 06:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220653/motif-bio-to-present-three-iclaprim-posters-at-industry-conference-in-san-francisco-next-month-220653.html Motif Bio meets FDA https://www.proactiveinvestors.com.au/companies/news/219763/motif-bio-meets-fda-219763.html Tue, 07 May 2019 06:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219763/motif-bio-meets-fda-219763.html Motif Bio partners up with Scottish biotech to develop iclaprim as cystic fibrosis lung infection treatment https://www.proactiveinvestors.com.au/companies/news/219454/motif-bio-partners-up-with-scottish-biotech-to-develop-iclaprim-as-cystic-fibrosis-lung-infection-treatment-219454.html Wed, 01 May 2019 13:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219454/motif-bio-partners-up-with-scottish-biotech-to-develop-iclaprim-as-cystic-fibrosis-lung-infection-treatment-219454.html Motif Bio higher as it presents data from Phase III iclaprim trial https://www.proactiveinvestors.com.au/companies/news/218650/motif-bio-higher-as-it-presents-data-from-phase-iii-iclaprim-trial-218650.html Tue, 16 Apr 2019 11:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/218650/motif-bio-higher-as-it-presents-data-from-phase-iii-iclaprim-trial-218650.html Motif Bio still hopeful of reaping the benefit from a productive year https://www.proactiveinvestors.com.au/companies/news/218554/motif-bio-still-hopeful-of-reaping-the-benefit-from-a-productive-year-218554.html Mon, 15 Apr 2019 11:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/218554/motif-bio-still-hopeful-of-reaping-the-benefit-from-a-productive-year-218554.html Motif Bio receives vote of confidence as it raises £2.7mln https://www.proactiveinvestors.com.au/companies/news/217201/motif-bio-receives-vote-of-confidence-as-it-raises-27mln-217201.html Tue, 26 Mar 2019 08:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/217201/motif-bio-receives-vote-of-confidence-as-it-raises-27mln-217201.html Motif Bio PLC says it is in the advanced stages of concluding a proposed placing to institutional and other investors https://www.proactiveinvestors.com.au/companies/news/217110/motif-bio-plc-says-it-is-in-the-advanced-stages-of-concluding-a-proposed-placing-to-institutional-and-other-investors-217110.html Mon, 25 Mar 2019 10:06:00 +1100 https://www.proactiveinvestors.com.au/companies/news/217110/motif-bio-plc-says-it-is-in-the-advanced-stages-of-concluding-a-proposed-placing-to-institutional-and-other-investors-217110.html Motif Bio surges as US FDA agrees to a meeting to discuss new drug application for novel antibiotic iclaprim https://www.proactiveinvestors.com.au/companies/news/216830/motif-bio-surges-as-us-fda-agrees-to-a-meeting-to-discuss-new-drug-application-for-novel-antibiotic-iclaprim-216830.html Wed, 20 Mar 2019 11:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/216830/motif-bio-surges-as-us-fda-agrees-to-a-meeting-to-discuss-new-drug-application-for-novel-antibiotic-iclaprim-216830.html Motif Bio appoints long-standing board member Bruce Williams as interim chairman, replacing Richard C.E. Morgan https://www.proactiveinvestors.com.au/companies/news/216618/motif-bio-appoints-long-standing-board-member-bruce-williams-as-interim-chairman-replacing-richard-ce-morgan-216618.html Mon, 18 Mar 2019 08:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/216618/motif-bio-appoints-long-standing-board-member-bruce-williams-as-interim-chairman-replacing-richard-ce-morgan-216618.html Motif Bio to manage cash aggressively after making loan repayment https://www.proactiveinvestors.com.au/companies/news/214781/motif-bio-to-manage-cash-aggressively-after-making-loan-repayment-214781.html Mon, 18 Feb 2019 07:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214781/motif-bio-to-manage-cash-aggressively-after-making-loan-repayment-214781.html Motif Bio seeks talks with FDA after iclaprim setback https://www.proactiveinvestors.com.au/companies/news/214611/motif-bio-seeks-talks-with-fda-after-iclaprim-setback-214611.html Thu, 14 Feb 2019 07:20:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214611/motif-bio-seeks-talks-with-fda-after-iclaprim-setback-214611.html Motif Bio to present positive iclaprim drug data in the US this week https://www.proactiveinvestors.com.au/companies/news/206277/motif-bio-to-present-positive-iclaprim-drug-data-in-the-us-this-week-206277.html Wed, 03 Oct 2018 08:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/206277/motif-bio-to-present-positive-iclaprim-drug-data-in-the-us-this-week-206277.html Motif Bio waiting on FDA approval of iclaprim after “tremendous” first half https://www.proactiveinvestors.com.au/companies/news/205625/motif-bio-waiting-on-fda-approval-of-iclaprim-after-tremendous-first-half-205625.html Tue, 25 Sep 2018 08:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205625/motif-bio-waiting-on-fda-approval-of-iclaprim-after-tremendous-first-half-205625.html Motif Bio: Latest data burnishes the credentials of new antibiotic https://www.proactiveinvestors.com.au/companies/news/204197/motif-bio-latest-data-burnishes-the-credentials-of-new-antibiotic-204197.html Wed, 05 Sep 2018 06:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204197/motif-bio-latest-data-burnishes-the-credentials-of-new-antibiotic-204197.html Motif Bio to present iclaprim data at microbiology conference in Portugal next month https://www.proactiveinvestors.com.au/companies/news/203110/motif-bio-to-present-iclaprim-data-at-microbiology-conference-in-portugal-next-month-203110.html Fri, 17 Aug 2018 06:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/203110/motif-bio-to-present-iclaprim-data-at-microbiology-conference-in-portugal-next-month-203110.html Motif Bio announces US FDA approval deadline for its antibiotic drug https://www.proactiveinvestors.com.au/companies/news/310120/motif-bio-announces-us-fda-approval-deadline-for-its-antibiotic-drug-10120.html Wed, 15 Aug 2018 06:53:00 +1000 https://www.proactiveinvestors.com.au/companies/news/310120/motif-bio-announces-us-fda-approval-deadline-for-its-antibiotic-drug-10120.html Motif Bio: US approval deadline for new antibiotic set for mid-February https://www.proactiveinvestors.com.au/companies/news/202816/motif-bio-us-approval-deadline-for-new-antibiotic-set-for-mid-february-202816.html Tue, 14 Aug 2018 06:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202816/motif-bio-us-approval-deadline-for-new-antibiotic-set-for-mid-february-202816.html Motif Bio secures new patents around optimal dose for iclaprim out to 2037 https://www.proactiveinvestors.com.au/companies/news/310068/motif-bio-secures-new-patents-around-optimal-dose-for-iclaprim-out-to-2037-10068.html Wed, 08 Aug 2018 11:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/310068/motif-bio-secures-new-patents-around-optimal-dose-for-iclaprim-out-to-2037-10068.html Motif Bio says two new US patents push exclusivity period over antibiotic out to 2037 https://www.proactiveinvestors.com.au/companies/news/202446/motif-bio-says-two-new-us-patents-push-exclusivity-period-over-antibiotic-out-to-2037-202446.html Wed, 08 Aug 2018 06:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/202446/motif-bio-says-two-new-us-patents-push-exclusivity-period-over-antibiotic-out-to-2037-202446.html Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim https://www.proactiveinvestors.com.au/companies/news/309607/motif-bio-completes-rolling-submission-of-nda-for-new-antibiotic-iclaprim-9607.html Mon, 18 Jun 2018 07:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309607/motif-bio-completes-rolling-submission-of-nda-for-new-antibiotic-iclaprim-9607.html Motif Bio completes FDA submission for Iclaprim antibiotic https://www.proactiveinvestors.com.au/companies/news/198840/motif-bio-completes-fda-submission-for-iclaprim-antibiotic-198840.html Thu, 14 Jun 2018 08:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198840/motif-bio-completes-fda-submission-for-iclaprim-antibiotic-198840.html Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard https://www.proactiveinvestors.com.au/companies/news/198583/pooled-data-from-phase-iii-trials-confirms-motif-bios-iclaprim-drug-is-safer-than-gold-standard-198583.html Mon, 11 Jun 2018 07:09:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198583/pooled-data-from-phase-iii-trials-confirms-motif-bios-iclaprim-drug-is-safer-than-gold-standard-198583.html Motif Bio boost as leading US investor snaps up stock https://www.proactiveinvestors.com.au/companies/news/197544/motif-bio-boost-as-leading-us-investor-snaps-up-stock-197544.html Wed, 23 May 2018 10:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197544/motif-bio-boost-as-leading-us-investor-snaps-up-stock-197544.html Motif Bio launches accelerated book-build placing to raise approximately £10mln to boost iclaprim investments https://www.proactiveinvestors.com.au/companies/news/197184/motif-bio-launches-accelerated-book-build-placing-to-raise-approximately-10mln-to-boost-iclaprim-investments-197184.html Thu, 17 May 2018 14:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197184/motif-bio-launches-accelerated-book-build-placing-to-raise-approximately-10mln-to-boost-iclaprim-investments-197184.html Motif Bio makes senior clinical development hire https://www.proactiveinvestors.com.au/companies/news/196615/motif-bio-makes-senior-clinical-development-hire-196615.html Wed, 09 May 2018 06:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196615/motif-bio-makes-senior-clinical-development-hire-196615.html Motif Bio to make two poster presentations to key conference https://www.proactiveinvestors.com.au/companies/news/196527/motif-bio-to-make-two-poster-presentations-to-key-conference-196527.html Tue, 08 May 2018 07:06:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196527/motif-bio-to-make-two-poster-presentations-to-key-conference-196527.html Motif Bio says results of Phase III trial to be published in peer-reviewed journal https://www.proactiveinvestors.com.au/companies/news/196122/motif-bio-says-results-of-phase-iii-trial-to-be-published-in-peer-reviewed-journal-196122.html Tue, 01 May 2018 07:18:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196122/motif-bio-says-results-of-phase-iii-trial-to-be-published-in-peer-reviewed-journal-196122.html Motif closes in on approvals, potentially looking for partnership opportunities https://www.proactiveinvestors.com.au/companies/news/195375/motif-closes-in-on-approvals-potentially-looking-for-partnership-opportunities-195375.html Thu, 19 Apr 2018 12:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195375/motif-closes-in-on-approvals-potentially-looking-for-partnership-opportunities-195375.html Motif Bio to present new Iclaprim safety and efficacy data at top European conference https://www.proactiveinvestors.com.au/companies/news/195344/motif-bio-to-present-new-iclaprim-safety-and-efficacy-data-at-top-european-conference-195344.html Thu, 19 Apr 2018 07:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195344/motif-bio-to-present-new-iclaprim-safety-and-efficacy-data-at-top-european-conference-195344.html Motif Bio evaluating commercialisation options as decision time approaches https://www.proactiveinvestors.com.au/companies/news/309093/motif-bio-evaluating-commercialisation-options-as-decision-time-approaches-9093.html Wed, 18 Apr 2018 15:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309093/motif-bio-evaluating-commercialisation-options-as-decision-time-approaches-9093.html Motif Bio starting to talk to doctors and hospitals about next-generation antibiotic https://www.proactiveinvestors.com.au/companies/news/194588/motif-bio-starting-to-talk-to-doctors-and-hospitals-about-next-generation-antibiotic-194588.html Tue, 10 Apr 2018 06:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194588/motif-bio-starting-to-talk-to-doctors-and-hospitals-about-next-generation-antibiotic-194588.html Motif Bio PLC gets ball rolling for iclaprim NDA https://www.proactiveinvestors.com.au/companies/news/308986/motif-bio-plc-gets-ball-rolling-for-iclaprim-nda-8986.html Tue, 03 Apr 2018 14:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308986/motif-bio-plc-gets-ball-rolling-for-iclaprim-nda-8986.html Motif Bio kicks off rolling new drug application with the FDA for iclaprim https://www.proactiveinvestors.com.au/companies/news/194128/motif-bio-kicks-off-rolling-new-drug-application-with-the-fda-for-iclaprim-194128.html Tue, 03 Apr 2018 12:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194128/motif-bio-kicks-off-rolling-new-drug-application-with-the-fda-for-iclaprim-194128.html Motif Bio Plc keen to make its 'best shot at goal' with iclaprim NDA https://www.proactiveinvestors.com.au/companies/news/308911/motif-bio-plc-keen-to-make-its-best-shot-at-goal-with-iclaprim-nda-8911.html Tue, 20 Mar 2018 16:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308911/motif-bio-plc-keen-to-make-its-best-shot-at-goal-with-iclaprim-nda-8911.html Motif Bio wants to make strongest possible submission to the US regulator as it targets second quarter for new drug application https://www.proactiveinvestors.com.au/companies/news/193438/motif-bio-wants-to-make-strongest-possible-submission-to-the-us-regulator-as-it-targets-second-quarter-for-new-drug-application-193438.html Tue, 20 Mar 2018 07:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193438/motif-bio-wants-to-make-strongest-possible-submission-to-the-us-regulator-as-it-targets-second-quarter-for-new-drug-application-193438.html Motif Bio chief medical officer to outline potential of its next-generation antibiotic at New York healthcare https://www.proactiveinvestors.com.au/companies/news/193355/motif-bio-chief-medical-officer-to-outline-potential-of-its-next-generation-antibiotic-at-new-york-healthcare-193355.html Mon, 19 Mar 2018 07:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193355/motif-bio-chief-medical-officer-to-outline-potential-of-its-next-generation-antibiotic-at-new-york-healthcare-193355.html Motif Bio to present at prestigious infectious diseases conference https://www.proactiveinvestors.com.au/companies/news/308785/motif-bio-to-present-at-prestigious-infectious-diseases-conference-8785.html Wed, 21 Feb 2018 19:44:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308785/motif-bio-to-present-at-prestigious-infectious-diseases-conference-8785.html Motif Bio chief financial officer Robert Dickey steps down https://www.proactiveinvestors.com.au/companies/news/191090/motif-bio-chief-financial-officer-robert-dickey-steps-down-191090.html Fri, 02 Feb 2018 15:44:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191090/motif-bio-chief-financial-officer-robert-dickey-steps-down-191090.html Motif Bio hails Cystic Fibrosis Foundation grant https://www.proactiveinvestors.com.au/companies/news/190081/motif-bio-hails-cystic-fibrosis-foundation-grant-190081.html Tue, 16 Jan 2018 08:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190081/motif-bio-hails-cystic-fibrosis-foundation-grant-190081.html Motif Bio zips higher as it pencils in more detail of REVIVE-1 trial https://www.proactiveinvestors.com.au/companies/news/189191/motif-bio-zips-higher-as-it-pencils-in-more-detail-of-revive-1-trial-189191.html Thu, 21 Dec 2017 15:54:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189191/motif-bio-zips-higher-as-it-pencils-in-more-detail-of-revive-1-trial-189191.html US companies set the benchmark for Motif Bio https://www.proactiveinvestors.com.au/companies/news/308371/us-companies-set-the-benchmark-for-motif-bio-8371.html Wed, 15 Nov 2017 15:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308371/us-companies-set-the-benchmark-for-motif-bio-8371.html Do Motif Bio's US rivals provide a value benchmark for the UK drug developer? https://www.proactiveinvestors.com.au/companies/news/187316/do-motif-bio-s-us-rivals-provide-a-value-benchmark-for-the-uk-drug-developer-187316.html Wed, 15 Nov 2017 14:57:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187316/do-motif-bio-s-us-rivals-provide-a-value-benchmark-for-the-uk-drug-developer-187316.html Motif Bio's US$20mln funding deal provides financial flexibility during US drug application process https://www.proactiveinvestors.com.au/companies/news/187300/Motif-Bio%27s-US-20mln-funding-deal-provides-financial-flexibility-during-US-drug-application-process-187300.html Wed, 15 Nov 2017 11:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187300/Motif-Bio%27s-US-20mln-funding-deal-provides-financial-flexibility-during-US-drug-application-process-187300.html Motif Bio PLC buoyed by early-stage data pointing to new indication for lead drug https://www.proactiveinvestors.com.au/companies/news/185167/motif-bio-plc-buoyed-by-early-stage-data-pointing-to-new-indication-for-lead-drug-185167.html Fri, 06 Oct 2017 06:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185167/motif-bio-plc-buoyed-by-early-stage-data-pointing-to-new-indication-for-lead-drug-185167.html Motif Bio on track to move forward with new drug application after Iclaprim success https://www.proactiveinvestors.com.au/companies/news/308197/motif-bio-on-track-to-move-forward-with-new-drug-application-after-iclaprim-success-8197.html Thu, 05 Oct 2017 14:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308197/motif-bio-on-track-to-move-forward-with-new-drug-application-after-iclaprim-success-8197.html The 'end of the marathon' for Motif Bio's Iclaprim https://www.proactiveinvestors.com.au/companies/news/308196/the-end-of-the-marathon-for-motif-bio-s-iclaprim-8196.html Thu, 05 Oct 2017 12:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308196/the-end-of-the-marathon-for-motif-bio-s-iclaprim-8196.html Motif Bio shares soar after Phase III clinical trial success https://www.proactiveinvestors.com.au/companies/news/185027/motif-bio-shares-soar-after-phase-iii-clinical-trial-success-185027.html Wed, 04 Oct 2017 13:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185027/motif-bio-shares-soar-after-phase-iii-clinical-trial-success-185027.html Motif Bio : The home plate beckons https://www.proactiveinvestors.com.au/companies/news/185054/motif-bio-the-home-plate-beckons-185054.html Wed, 04 Oct 2017 12:15:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185054/motif-bio-the-home-plate-beckons-185054.html Motif Bio remains on track to make new drug submission early next year https://www.proactiveinvestors.com.au/companies/news/184816/motif-bio-remains-on-track-to-make-new-drug-submission-early-next-year-184816.html Fri, 29 Sep 2017 11:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184816/motif-bio-remains-on-track-to-make-new-drug-submission-early-next-year-184816.html Motif Bio keen for UK shareholder participation in New York investor meeting https://www.proactiveinvestors.com.au/companies/news/308104/motif-bio-keen-for-uk-shareholder-participation-in-new-york-investor-meeting-8104.html Tue, 19 Sep 2017 11:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308104/motif-bio-keen-for-uk-shareholder-participation-in-new-york-investor-meeting-8104.html Motif Bio shares rise after treatment gets FDA orphan drug designation https://www.proactiveinvestors.com.au/companies/news/184079/motif-bio-shares-rise-after-treatment-gets-fda-orphan-drug-designation-184079.html Fri, 15 Sep 2017 13:38:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184079/motif-bio-shares-rise-after-treatment-gets-fda-orphan-drug-designation-184079.html Motif Bio close to hitting home run after latest clinical trial milestone https://www.proactiveinvestors.com.au/companies/news/182211/motif-bio-close-to-hitting-home-run-after-latest-clinical-trial-milestone-182211.html Wed, 09 Aug 2017 14:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182211/motif-bio-close-to-hitting-home-run-after-latest-clinical-trial-milestone-182211.html Motif Bio reaches “key milestone” as last patient completes treatment in REVIVE-2 clinical trial https://www.proactiveinvestors.com.au/companies/news/182187/motif-bio-reaches-key-milestone-as-last-patient-completes-treatment-in-revive-2-clinical-trial-182187.html Wed, 09 Aug 2017 09:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/182187/motif-bio-reaches-key-milestone-as-last-patient-completes-treatment-in-revive-2-clinical-trial-182187.html Motif Bio ups Robert Bertoldi's consultancy fee https://www.proactiveinvestors.com.au/companies/news/181042/motif-bio-ups-robert-bertoldi-s-consultancy-fee-181042.html Tue, 18 Jul 2017 07:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/181042/motif-bio-ups-robert-bertoldi-s-consultancy-fee-181042.html Motif Bio to make three poster presentations at annual Infectious Diseases conference https://www.proactiveinvestors.com.au/companies/news/180436/motif-bio-to-make-three-poster-presentations-at-annual-infectious-diseases-conference-180436.html Thu, 06 Jul 2017 14:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/180436/motif-bio-to-make-three-poster-presentations-at-annual-infectious-diseases-conference-180436.html Motif Bio gearing up to present at major conference on infectious diseases https://www.proactiveinvestors.com.au/companies/news/307753/motif-bio-gearing-up-to-present-at-major-conference-on-infectious-diseases-7753.html Thu, 06 Jul 2017 11:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307753/motif-bio-gearing-up-to-present-at-major-conference-on-infectious-diseases-7753.html Motif Bio medical chief to present at prestigious infectious diseases conference https://www.proactiveinvestors.com.au/companies/news/179652/motif-bio-medical-chief-to-present-at-prestigious-infectious-diseases-conference-179652.html Thu, 22 Jun 2017 06:24:00 +1000 https://www.proactiveinvestors.com.au/companies/news/179652/motif-bio-medical-chief-to-present-at-prestigious-infectious-diseases-conference-179652.html finnCap repeats 'buy' on Motif Bio, but trims target for dilution after recent placing https://www.proactiveinvestors.com.au/companies/news/178900/finncap-repeats-buy-on-motif-bio-but-trims-target-for-dilution-after-recent-placing-178900.html Wed, 07 Jun 2017 10:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178900/finncap-repeats-buy-on-motif-bio-but-trims-target-for-dilution-after-recent-placing-178900.html Motif Bio successfully completes latest fundraise; raises more than originally planned https://www.proactiveinvestors.com.au/companies/news/178771/motif-bio-successfully-completes-latest-fundraise-raises-more-than-originally-planned-178771.html Mon, 05 Jun 2017 09:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178771/motif-bio-successfully-completes-latest-fundraise-raises-more-than-originally-planned-178771.html Motif Bio set to raise US$25mln to fund the commercialisation of new antibiotic https://www.proactiveinvestors.com.au/companies/news/178685/motif-bio-set-to-raise-us25mln-to-fund-the-commercialisation-of-new-antibiotic-178685.html Fri, 02 Jun 2017 14:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/178685/motif-bio-set-to-raise-us25mln-to-fund-the-commercialisation-of-new-antibiotic-178685.html Motif Bio adds three to strengthen medical advisory board https://www.proactiveinvestors.com.au/companies/news/177577/motif-bio-adds-three-to-strengthen-medical-advisory-board-177577.html Wed, 10 May 2017 08:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177577/motif-bio-adds-three-to-strengthen-medical-advisory-board-177577.html Motif Bio appoints Dr Craig Albanese as new non-executive director https://www.proactiveinvestors.com.au/companies/news/177364/motif-bio-appoints-dr-craig-albanese-as-new-non-executive-director-177364.html Fri, 05 May 2017 07:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177364/motif-bio-appoints-dr-craig-albanese-as-new-non-executive-director-177364.html Motif Bio looks forward to more iclaprim data after 'major achievement' with first results https://www.proactiveinvestors.com.au/companies/news/177153/motif-bio-looks-forward-to-more-iclaprim-data-after-major-achievement-with-first-results-177153.html Tue, 02 May 2017 09:16:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177153/motif-bio-looks-forward-to-more-iclaprim-data-after-major-achievement-with-first-results-177153.html Phase III Iclaprim trial results 'bode very well' for Motif Bio, says Northland Capital's Alexandre https://www.proactiveinvestors.com.au/companies/news/307312/phase-iii-iclaprim-trial-results-bode-very-well-for-motif-bio-says-northland-capital-s-alexandre-7312.html Thu, 20 Apr 2017 14:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307312/phase-iii-iclaprim-trial-results-bode-very-well-for-motif-bio-says-northland-capital-s-alexandre-7312.html 'All good news' from Motif Bio's Phase III clinical trial of Iclaprim, says CEO Graham Lumsden https://www.proactiveinvestors.com.au/companies/news/307304/-all-good-news-from-motif-bio-s-phase-iii-clinical-trial-of-iclaprim-says-ceo-graham-lumsden-7304.html Wed, 19 Apr 2017 14:02:00 +1000 https://www.proactiveinvestors.com.au/companies/news/307304/-all-good-news-from-motif-bio-s-phase-iii-clinical-trial-of-iclaprim-says-ceo-graham-lumsden-7304.html Drug developer Motif Bio close to hitting home run after positive headline clinical trial results https://www.proactiveinvestors.com.au/companies/news/176530/drug-developer-motif-bio-close-to-hitting-home-run-after-positive-headline-clinical-trial-results-176530.html Tue, 18 Apr 2017 11:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176530/drug-developer-motif-bio-close-to-hitting-home-run-after-positive-headline-clinical-trial-results-176530.html Drug developer Motif Bio's antibiotic successfully completes first phase III trial https://www.proactiveinvestors.com.au/companies/news/176506/drug-developer-motif-bio-s-antibiotic-successfully-completes-first-phase-iii-trial-176506.html Tue, 18 Apr 2017 06:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176506/drug-developer-motif-bio-s-antibiotic-successfully-completes-first-phase-iii-trial-176506.html Motif Bio celebrates 'major milestone' in antibiotic trial' https://www.proactiveinvestors.com.au/companies/news/306822/motif-bio-celebrates-major-milestone-in-antibiotic-trial--6822.html Tue, 31 Jan 2017 14:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306822/motif-bio-celebrates-major-milestone-in-antibiotic-trial--6822.html Motif Bio passes major landmark as last patient in phase III trial is treated https://www.proactiveinvestors.com.au/companies/news/172391/motif-bio-passes-major-landmark-as-last-patient-in-phase-iii-trial-is-treated-172391.html Tue, 31 Jan 2017 10:42:00 +1100 https://www.proactiveinvestors.com.au/companies/news/172391/motif-bio-passes-major-landmark-as-last-patient-in-phase-iii-trial-is-treated-172391.html Shares in Motif Bio could rally to 35p says Zak Mir https://www.proactiveinvestors.com.au/companies/news/306804/shares-in-motif-bio-could-rally-to-35p-says-zak-mir-6804.html Fri, 27 Jan 2017 10:18:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306804/shares-in-motif-bio-could-rally-to-35p-says-zak-mir-6804.html Milestones passing by rapidly for Motif Bio https://www.proactiveinvestors.com.au/companies/news/171895/milestones-passing-by-rapidly-for-motif-bio-171895.html Thu, 19 Jan 2017 15:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171895/milestones-passing-by-rapidly-for-motif-bio-171895.html Motif Bio PLC announces new chief financial officer https://www.proactiveinvestors.com.au/companies/news/171790/motif-bio-plc-announces-new-chief-financial-officer-171790.html Wed, 18 Jan 2017 15:51:00 +1100 https://www.proactiveinvestors.com.au/companies/news/171790/motif-bio-plc-announces-new-chief-financial-officer-171790.html Motif Bio successfully raises US$25mln https://www.proactiveinvestors.com.au/companies/news/169458/motif-bio-successfully-raises-us25mln-169458.html Thu, 24 Nov 2016 12:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/169458/motif-bio-successfully-raises-us25mln-169458.html Motif Bio worth 114p, says growth company specialist https://www.proactiveinvestors.com.au/companies/news/169268/motif-bio-worth-114p-says-growth-company-specialist-169268.html Mon, 21 Nov 2016 13:28:00 +1100 https://www.proactiveinvestors.com.au/companies/news/169268/motif-bio-worth-114p-says-growth-company-specialist-169268.html Motif Bio outlines plans to raise US$25mln and join NASDAQ https://www.proactiveinvestors.com.au/companies/news/169179/motif-bio-outlines-plans-to-raise-us25mln-and-join-nasdaq-169179.html Fri, 18 Nov 2016 07:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/169179/motif-bio-outlines-plans-to-raise-us25mln-and-join-nasdaq-169179.html Shard Market Eye: Motif Bio plc https://www.proactiveinvestors.com.au/companies/news/276432/shard-market-eye-motif-bio-plc-26432.html Thu, 03 Nov 2016 08:03:00 +1100 https://www.proactiveinvestors.com.au/companies/news/276432/shard-market-eye-motif-bio-plc-26432.html Motif Bio remains confident over funding https://www.proactiveinvestors.com.au/companies/news/168239/motif-bio-remains-confident-over-funding-168239.html Mon, 31 Oct 2016 07:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/168239/motif-bio-remains-confident-over-funding-168239.html Motif Bio plc expects data readout earlier than forecast https://www.proactiveinvestors.com.au/companies/news/163634/motif-bio-plc-expects-data-readout-earlier-than-forecast-163634.html Thu, 08 Sep 2016 06:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/163634/motif-bio-plc-expects-data-readout-earlier-than-forecast-163634.html Northland Capital Partners View on the City - Motif Bio plc https://www.proactiveinvestors.com.au/companies/news/275858/northland-capital-partners-view-on-the-city-motif-bio-plc-25858.html Fri, 26 Aug 2016 08:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/275858/northland-capital-partners-view-on-the-city-motif-bio-plc-25858.html Motif Bio flagship superbug drug reaches final stage development https://www.proactiveinvestors.com.au/companies/news/129362/motif-bio-flagship-superbug-drug-reaches-final-stage-development-129362.html Tue, 16 Aug 2016 07:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/129362/motif-bio-flagship-superbug-drug-reaches-final-stage-development-129362.html Motif Bio puts US listing plans on ice https://www.proactiveinvestors.com.au/companies/news/129143/motif-bio-puts-us-listing-plans-on-ice-129143.html Tue, 09 Aug 2016 06:49:00 +1000 https://www.proactiveinvestors.com.au/companies/news/129143/motif-bio-puts-us-listing-plans-on-ice-129143.html SHARD MARKET EYE: MOTIF BIO https://www.proactiveinvestors.com.au/companies/news/275655/shard-market-eye-motif-bio-25655.html Wed, 03 Aug 2016 13:08:00 +1000 https://www.proactiveinvestors.com.au/companies/news/275655/shard-market-eye-motif-bio-25655.html Shard Market Eye: Motif Bio https://www.proactiveinvestors.com.au/companies/news/275639/shard-market-eye-motif-bio-25639.html Wed, 03 Aug 2016 09:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/275639/shard-market-eye-motif-bio-25639.html Broker upgrade for Motif Bio with NASDAQ listing ahead https://www.proactiveinvestors.com.au/companies/news/128709/broker-upgrade-for-motif-bio-with-nasdaq-listing-ahead-128709.html Wed, 27 Jul 2016 14:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/128709/broker-upgrade-for-motif-bio-with-nasdaq-listing-ahead-128709.html Motif Bio plans to raise up to US$60mln from US investors https://www.proactiveinvestors.com.au/companies/news/128140/motif-bio-plans-to-raise-up-to-us60mln-from-us-investors-128140.html Wed, 13 Jul 2016 10:38:00 +1000 https://www.proactiveinvestors.com.au/companies/news/128140/motif-bio-plans-to-raise-up-to-us60mln-from-us-investors-128140.html Motif Bio in a strong position to build pipeline says chief https://www.proactiveinvestors.com.au/companies/news/304927/motif-bio-in-a-strong-position-to-build-pipeline-says-chief-4927.html Thu, 21 Apr 2016 14:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/304927/motif-bio-in-a-strong-position-to-build-pipeline-says-chief-4927.html Motif Bio looks to add to drug pipeline https://www.proactiveinvestors.com.au/companies/news/125000/motif-bio-looks-to-add-to-drug-pipeline-125000.html Wed, 20 Apr 2016 06:48:00 +1000 https://www.proactiveinvestors.com.au/companies/news/125000/motif-bio-looks-to-add-to-drug-pipeline-125000.html Motif Bio adds two new faces to senior team https://www.proactiveinvestors.com.au/companies/news/124792/motif-bio-adds-two-new-faces-to-senior-team-124792.html Thu, 14 Apr 2016 07:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/124792/motif-bio-adds-two-new-faces-to-senior-team-124792.html Motif Bio PLC invited to prestigious life sciences partnering conference https://www.proactiveinvestors.com.au/companies/news/124010/motif-bio-plc-invited-to-prestigious-life-sciences-partnering-conference-124010.html Wed, 23 Mar 2016 08:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/124010/motif-bio-plc-invited-to-prestigious-life-sciences-partnering-conference-124010.html Motif Bio PLC chief looking to add “one or two partners during 2016” https://www.proactiveinvestors.com.au/companies/news/304782/motif-bio-plc-chief-looking-to-add-one-or-two-partners-during-2016-4782.html Wed, 16 Mar 2016 15:22:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304782/motif-bio-plc-chief-looking-to-add-one-or-two-partners-during-2016-4782.html Motif doses first patient for phase III trials https://www.proactiveinvestors.com.au/companies/news/123191/motif-doses-first-patient-for-phase-iii-trials-123191.html Wed, 02 Mar 2016 16:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/123191/motif-doses-first-patient-for-phase-iii-trials-123191.html Motif BIo chief “very confident” for Phase III iclaprim trial https://www.proactiveinvestors.com.au/companies/news/304713/motif-bio-chief-very-confident-for-phase-iii-iclaprim-trial-4713.html Wed, 02 Mar 2016 15:02:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304713/motif-bio-chief-very-confident-for-phase-iii-iclaprim-trial-4713.html Motif Bio chief talks up potential US listing https://www.proactiveinvestors.com.au/companies/news/304577/motif-bio-chief-talks-up-potential-us-listing-4577.html Mon, 25 Jan 2016 15:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304577/motif-bio-chief-talks-up-potential-us-listing-4577.html Motif Bio eyes NASDAQ valuations as it mulls US move https://www.proactiveinvestors.com.au/companies/news/121718/motif-bio-eyes-nasdaq-valuations-as-it-mulls-us-move-121718.html Mon, 25 Jan 2016 14:01:00 +1100 https://www.proactiveinvestors.com.au/companies/news/121718/motif-bio-eyes-nasdaq-valuations-as-it-mulls-us-move-121718.html Motif Bio says NASDAQ listing an option as bank appointed https://www.proactiveinvestors.com.au/companies/news/121687/motif-bio-says-nasdaq-listing-an-option-as-bank-appointed-121687.html Mon, 25 Jan 2016 07:51:00 +1100 https://www.proactiveinvestors.com.au/companies/news/121687/motif-bio-says-nasdaq-listing-an-option-as-bank-appointed-121687.html Four drug stocks to watch in phase III next year https://www.proactiveinvestors.com.au/companies/news/170876/four-drug-stocks-to-watch-in-phase-iii-next-year-170876.html Wed, 13 Jan 2016 13:01:00 +1100 https://www.proactiveinvestors.com.au/companies/news/170876/four-drug-stocks-to-watch-in-phase-iii-next-year-170876.html Motif Bio says iclaprim trial supplies are ready to ship https://www.proactiveinvestors.com.au/companies/news/120457/motif-bio-says-iclaprim-trial-supplies-are-ready-to-ship-120457.html Tue, 15 Dec 2015 12:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/120457/motif-bio-says-iclaprim-trial-supplies-are-ready-to-ship-120457.html Motif Bio to present at prestigious US event https://www.proactiveinvestors.com.au/companies/news/120111/motif-bio-to-present-at-prestigious-us-event-120111.html Mon, 07 Dec 2015 09:37:00 +1100 https://www.proactiveinvestors.com.au/companies/news/120111/motif-bio-to-present-at-prestigious-us-event-120111.html Motif Bio boosted by FDA dosage decision https://www.proactiveinvestors.com.au/companies/news/304406/motif-bio-boosted-by-fda-dosage-decision-4406.html Wed, 25 Nov 2015 10:08:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304406/motif-bio-boosted-by-fda-dosage-decision-4406.html Motif Bio sets dosage for iclaprim phase III trial https://www.proactiveinvestors.com.au/companies/news/119613/motif-bio-sets-dosage-for-iclaprim-phase-iii-trial-119613.html Tue, 24 Nov 2015 07:49:00 +1100 https://www.proactiveinvestors.com.au/companies/news/119613/motif-bio-sets-dosage-for-iclaprim-phase-iii-trial-119613.html Motif Bio boss on EU approvals for Iclaprim trials https://www.proactiveinvestors.com.au/companies/news/304360/motif-bio-boss-on-eu-approvals-for-iclaprim-trials-4360.html Thu, 12 Nov 2015 08:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304360/motif-bio-boss-on-eu-approvals-for-iclaprim-trials-4360.html Motif Bio makes progress with EU regulators https://www.proactiveinvestors.com.au/companies/news/117340/motif-bio-makes-progress-with-eu-regulators-117340.html Wed, 11 Nov 2015 11:40:00 +1100 https://www.proactiveinvestors.com.au/companies/news/117340/motif-bio-makes-progress-with-eu-regulators-117340.html Motif Bio well-placed as 'antibiotic apocalypse' awareness grows says Zeus https://www.proactiveinvestors.com.au/companies/news/117088/motif-bio-well-placed-as-antibiotic-apocalypse-awareness-grows-says-zeus-117088.html Wed, 04 Nov 2015 16:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/117088/motif-bio-well-placed-as-antibiotic-apocalypse-awareness-grows-says-zeus-117088.html Motif BIo to present at European conference https://www.proactiveinvestors.com.au/companies/news/116680/motif-bio-to-present-at-european-conference-116680.html Tue, 27 Oct 2015 07:51:00 +1100 https://www.proactiveinvestors.com.au/companies/news/116680/motif-bio-to-present-at-european-conference-116680.html Motif Bio unveils partner for antibiotic trial https://www.proactiveinvestors.com.au/companies/news/116283/motif-bio-unveils-partner-for-antibiotic-trial-116283.html Fri, 16 Oct 2015 15:41:00 +1100 https://www.proactiveinvestors.com.au/companies/news/116283/motif-bio-unveils-partner-for-antibiotic-trial-116283.html Motif Bio chief hails new partner as best in antibiotic space https://www.proactiveinvestors.com.au/companies/news/304279/motif-bio-chief-hails-new-partner-as-best-in-antibiotic-space-4279.html Fri, 16 Oct 2015 14:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/304279/motif-bio-chief-hails-new-partner-as-best-in-antibiotic-space-4279.html Motif Bio encouraged by additional data for antibiotic https://www.proactiveinvestors.com.au/companies/news/116151/motif-bio-encouraged-by-additional-data-for-antibiotic-116151.html Tue, 13 Oct 2015 08:14:00 +1100 https://www.proactiveinvestors.com.au/companies/news/116151/motif-bio-encouraged-by-additional-data-for-antibiotic-116151.html UPDATE - Motif Bio to share Iclaprim data at San Diego’s Infectious Disease Week https://www.proactiveinvestors.com.au/companies/news/111212/update-motif-bio-to-share-iclaprim-data-at-san-diegos-infectious-disease-week-111212.html Tue, 29 Sep 2015 12:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/111212/update-motif-bio-to-share-iclaprim-data-at-san-diegos-infectious-disease-week-111212.html MotifBio looking at regional partners for Iclaprim https://www.proactiveinvestors.com.au/companies/news/304181/motifbio-looking-at-regional-partners-for-iclaprim-4181.html Fri, 25 Sep 2015 07:52:00 +1000 https://www.proactiveinvestors.com.au/companies/news/304181/motifbio-looking-at-regional-partners-for-iclaprim-4181.html Motif Bio valued at "extremely attractive level", says broker https://www.proactiveinvestors.com.au/companies/news/111101/motif-bio-valued-at-extremely-attractive-level-says-broker-111101.html Thu, 24 Sep 2015 11:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/111101/motif-bio-valued-at-extremely-attractive-level-says-broker-111101.html Motif drug awarded fast track designation by US regulator https://www.proactiveinvestors.com.au/companies/news/110481/motif-drug-awarded-fast-track-designation-by-us-regulator-110481.html Thu, 03 Sep 2015 11:24:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110481/motif-drug-awarded-fast-track-designation-by-us-regulator-110481.html Motif Bio chief hails company's transformation https://www.proactiveinvestors.com.au/companies/news/110333/motif-bio-chief-hails-company-s-transformation-110333.html Thu, 27 Aug 2015 07:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110333/motif-bio-chief-hails-company-s-transformation-110333.html Motif Bio: Study reveals antibiotic's potency https://www.proactiveinvestors.com.au/companies/news/110205/motif-bio-study-reveals-antibiotic-s-potency-110205.html Mon, 24 Aug 2015 15:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/110205/motif-bio-study-reveals-antibiotic-s-potency-110205.html Motif Bio CEO: Investors can take confidence from Iclaprim study results https://www.proactiveinvestors.com.au/companies/news/304086/motif-bio-ceo-investors-can-take-confidence-from-iclaprim-study-results-4086.html Mon, 24 Aug 2015 14:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/304086/motif-bio-ceo-investors-can-take-confidence-from-iclaprim-study-results-4086.html Motif Bio set to receive £22mln following FDA rubberstamp https://www.proactiveinvestors.com.au/companies/news/109229/motif-bio-set-to-receive-22mln-following-fda-rubberstamp-109229.html Wed, 22 Jul 2015 06:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/109229/motif-bio-set-to-receive-22mln-following-fda-rubberstamp-109229.html UPDATE - Motif Bio antibiotic given boost by US regulator https://www.proactiveinvestors.com.au/companies/news/109103/update-motif-bio-antibiotic-given-boost-by-us-regulator-109103.html Fri, 17 Jul 2015 20:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/109103/update-motif-bio-antibiotic-given-boost-by-us-regulator-109103.html Motif Bio boss looks towards Phase III trials for Iclaprim https://www.proactiveinvestors.com.au/companies/news/303957/motif-bio-boss-looks-towards-phase-iii-trials-for-iclaprim-3957.html Fri, 17 Jul 2015 13:58:00 +1000 https://www.proactiveinvestors.com.au/companies/news/303957/motif-bio-boss-looks-towards-phase-iii-trials-for-iclaprim-3957.html Motif Bio adds infectious disease expert to scientific advisory board https://www.proactiveinvestors.com.au/companies/news/109007/motif-bio-adds-infectious-disease-expert-to-scientific-advisory-board-109007.html Wed, 15 Jul 2015 06:53:00 +1000 https://www.proactiveinvestors.com.au/companies/news/109007/motif-bio-adds-infectious-disease-expert-to-scientific-advisory-board-109007.html UPDATE - Motif Bio gets £22mln shot in the arm https://www.proactiveinvestors.com.au/companies/news/108276/update-motif-bio-gets-22mln-shot-in-the-arm-108276.html Tue, 23 Jun 2015 16:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/108276/update-motif-bio-gets-22mln-shot-in-the-arm-108276.html Motif Bio making rapid progress https://www.proactiveinvestors.com.au/companies/news/107853/motif-bio-making-rapid-progress-107853.html Tue, 09 Jun 2015 07:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/107853/motif-bio-making-rapid-progress-107853.html UPDATE - Motif Bio chooses contractor route for phase III antibiotic trial https://www.proactiveinvestors.com.au/companies/news/107563/update-motif-bio-chooses-contractor-route-for-phase-iii-antibiotic-trial-107563.html Mon, 01 Jun 2015 13:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/107563/update-motif-bio-chooses-contractor-route-for-phase-iii-antibiotic-trial-107563.html Motif Bio boosted by receipt of FDA confirmation https://www.proactiveinvestors.com.au/companies/news/107463/motif-bio-boosted-by-receipt-of-fda-confirmation-107463.html Thu, 28 May 2015 06:49:00 +1000 https://www.proactiveinvestors.com.au/companies/news/107463/motif-bio-boosted-by-receipt-of-fda-confirmation-107463.html Motif Bio to cash in on super-bug drug market, says broker https://www.proactiveinvestors.com.au/companies/news/107420/motif-bio-to-cash-in-on-super-bug-drug-market-says-broker-107420.html Wed, 27 May 2015 11:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/107420/motif-bio-to-cash-in-on-super-bug-drug-market-says-broker-107420.html UPDATE - MotifBio and Summit Therapeutics on the warpath to beat drug resistant bacteria https://www.proactiveinvestors.com.au/companies/news/106758/update-motifbio-and-summit-therapeutics-on-the-warpath-to-beat-drug-resistant-bacteria-106758.html Thu, 14 May 2015 14:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/106758/update-motifbio-and-summit-therapeutics-on-the-warpath-to-beat-drug-resistant-bacteria-106758.html Motif Bio to present at prestigious biotech convention https://www.proactiveinvestors.com.au/companies/news/106602/motif-bio-to-present-at-prestigious-biotech-convention-106602.html Tue, 12 May 2015 07:04:00 +1000 https://www.proactiveinvestors.com.au/companies/news/106602/motif-bio-to-present-at-prestigious-biotech-convention-106602.html Motif Bio has 'considerable potential upside', according to Shard https://www.proactiveinvestors.com.au/companies/news/68814/motif-bio-has-considerable-potential-upside-according-to-shard-80133.html Fri, 08 May 2015 14:06:00 +1000 https://www.proactiveinvestors.com.au/companies/news/68814/motif-bio-has-considerable-potential-upside-according-to-shard-80133.html Motif Bio selected to pitch to pharma dealmakers in Vienna later this month https://www.proactiveinvestors.com.au/companies/news/68752/motif-bio-selected-to-pitch-to-pharma-dealmakers-in-vienna-later-this-month-80068.html Thu, 07 May 2015 06:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/68752/motif-bio-selected-to-pitch-to-pharma-dealmakers-in-vienna-later-this-month-80068.html Motif Bio chief on vast market opportunity for lead drug https://www.proactiveinvestors.com.au/companies/news/303255/motif-bio-chief-on-vast-market-opportunity-for-lead-drug-3711.html Mon, 27 Apr 2015 15:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/303255/motif-bio-chief-on-vast-market-opportunity-for-lead-drug-3711.html Motif Bio confident about partner interest in Iclaprim https://www.proactiveinvestors.com.au/companies/news/303221/motif-bio-confident-about-partner-interest-in-iclaprim-3676.html Thu, 16 Apr 2015 08:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/303221/motif-bio-confident-about-partner-interest-in-iclaprim-3676.html UPDATE - Motif Bio given green light to start phase III clinical trials on breakthrough antibiotic https://www.proactiveinvestors.com.au/companies/news/68040/update-motif-bio-given-green-light-to-start-phase-iii-clinical-trials-on-breakthrough-antibiotic--79290.html Motif Bio has been given the green light to begin phase III clinical trials on its next-generation antibiotic by the American regulator.

]]>
Wed, 15 Apr 2015 13:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/68040/update-motif-bio-given-green-light-to-start-phase-iii-clinical-trials-on-breakthrough-antibiotic--79290.html
Motif Bio in ‘right place at right time’ – CEO https://www.proactiveinvestors.com.au/companies/news/303188/motif-bio-in-right-place-at-right-time-ceo-3642.html Thu, 02 Apr 2015 10:56:00 +1100 https://www.proactiveinvestors.com.au/companies/news/303188/motif-bio-in-right-place-at-right-time-ceo-3642.html Motif Bio ready to make mark in next generation of antibiotics https://www.proactiveinvestors.com.au/companies/news/67740/motif-bio-ready-to-make-mark-in-next-generation-of-antibiotics--78960.html Motif Bio is one of those extremely rare life sciences company that comes to a market with a drug ready to go into the final phase of clinical trials.

]]>
Thu, 02 Apr 2015 07:59:00 +1100 https://www.proactiveinvestors.com.au/companies/news/67740/motif-bio-ready-to-make-mark-in-next-generation-of-antibiotics--78960.html
Motif Bio races to 50% premium on market debut https://www.proactiveinvestors.com.au/companies/news/67741/motif-bio-races-to-50-premium-on-market-debut-78961.html Thu, 02 Apr 2015 07:55:00 +1100 https://www.proactiveinvestors.com.au/companies/news/67741/motif-bio-races-to-50-premium-on-market-debut-78961.html